2024-05-28 16:13:42 ET
Summary
- Altimmune is developing pemvidutide, a dual agonist of GLP-1 and glucagon receptors, with promising phase 2 data already seen in obesity.
- A phase 2 trial in metabolic dysfunction-associated steatohepatitis, or MASH, is underway, and set to produce a readout in Q1'25.
- Altimmune also has an end-of-phase 2 meeting with the US FDA in Q3'24, which could provide clarity on requirements for a phase 3 program in obesity.
...
Read the full article on Seeking Alpha
For further details see:
Altimmune's Pemvidutide Is Not To Be Dismissed